Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 9, 2007, Pages 3185-3189

  Traunmüller, Friederike ^a   Zeitlinger, Markus ^a   Zeleny, Petra ^a   Müller, Markus ^a   Joukhadar, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG INDICATION; HUMAN; INTERSTITIAL FLUID; MALE; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKELETAL MUSCLE; SKIN INFECTION; SOFT TISSUE INFECTION; STEADY STATE; SUBCUTANEOUS FAT; VOLUNTEER;

ADIPOSE TISSUE; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CLARITHROMYCIN; HALF-LIFE; HUMANS; MALE; MICRODIALYSIS; MUSCLE, SKELETAL; PROTEIN BINDING; TISSUE DISTRIBUTION;

EID: 35948929765     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00532-07     Document Type: Article

References (25)

1. Amsden, G. W. 1996. Advanced generation macrolides: tissue-directed antibiotics. Int. J. Antimicrob. Agents 18:S11-S15.
2. Craig, W. A., S. Kiem, and D. R. Andes. 2002. Free drug 24-hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin. Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother., San Diego, CA, abstr. A-1264. American Society for Microbiology, Washington, DC.
3. Bouw, M. R., and M. Hammarlund-Udenaes. 1998. Methodological aspects of the use of a calibrator in in vivo microdialysis - further development of the retrodialysis method. Pharm. Res. 15:1673-1679.
4. Burkhardt, O., K. Borner, H. Staß, G. Beyer, M. Allewelt, C. E. Nord, and H. Lode. 2002. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand. Infect. Dis. 34:898-903.
5. Carbon, C. 1995. Clinical relevance of intracellular and extracellular concentrations of macrolides. Infection 23(Suppl. 1):S10-S14.
6. Chu, S., R. Deaton, and J. Cavanaugh. 1992. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob. Agents Chemother. 36:1147-1150.
7. Chu, S., D. S. Wilson, R. L. Deaton, A. V. Mackenthun, C. N. Eason, and J. H. Cavanaugh. 1993. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J. Clin. Pharmacol. 33:719-726.
8. Fernandes, P. B., N. Ramer, R. A. Rode, and L. Freiberg. 1988. Bioassay for A-56268 (TE-031) and identification of its major metabolite 14-hydroxy-6-O-methyl erythromycin. Eur. J. Clin. Microbiol. Infect. Dis. 7:73-76.
9. Fietta, A., C. Merlini, and G. Gialdroni Grassi. 1997. Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes. J. Chemother. 9:23-31.
10. Fish, D. N., M. H. Gotfried, L. H. Danziger, and K. A. Rodvold. 1994. Penetration of clarithromycin into lung tissues from patients undergoing lung resection. Antimicrob. Agents Chemother. 38:876-878.
11. Goldstein, E. J., D. M. Citron, C. V. Merriam, Y. Warren, and K. Tyrrell. 2000. Comparative in vitro activities of ABT-773 against aerobic and anaerobic pathogens isolated from skin and soft-tissue animal and human bite wound infections. Antimicrob. Agents Chemother. 44:2525-2529.
12. Haraldsson, B. 1986. Physiological studies of macromolecular transport across capillary walls. Studies on continuous capillaries in rat skeletal muscle. Acta Physiol. Scand. Suppl. 553:1-40.
13. Honeybourne, D., F. Kees, J. M. Andrews, D. Baldwin, and R. Wise. 1994. The levels of clarithromycin and its 14-hydroxy metabolite in the lung. Eur. Respir. J. 7:1275-1280.
14. Hoover, W. W., M. S. Barrett, and R. N. Jones. 1992. Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin. Diagn. Microbiol. Infect. Dis. 15:259-266.
15. Joukhadar, C., and M. Müller. 2005. Microdialysis. Current applications and clinical pharmacokinetic studies and its potential role in the future. Clin. Pharmacokinet. 44:895-913.
16. Martin, J. R., P. Johnson, and M. F. Miller. 1985. Uptake, accumulation, and egress of erythromycin by tissue culture cells of human origin. Antimicrob. Agents Chemother. 27:314-319.
17. Martin, S. J., C. G. Garvin, C. R. McBurney, and E. G. Sahloff. 2001. The activity of 14-hydroxy clarithromycin, alone and in combination with clarithromycin, against penicillin- and erythromycin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 47:581-587.
18. McLeod, C. M., R. J. Schotzinger, G. F. Vanhove, and R. T. Bachand. 1999. Pharmacokinetics and safety of a once-daily clarithromycin formulation. Adv. Ther. 16:1-12.
19. Parish, L. C. and The Clarithromycin Study Group. 1993. Clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies. Int. J. Dermatol. 32:528-532.
20. Parsad, D., R. Pandhi, and S. Dogra. 2003. A guide to selection and appropriate use of macrolides in skin infections. Am. J. Clin. Dermatol. 4:389-397.
21. Rodvold, K. A., M. H. Gotfried, L. H. Danziger, and R. J. Servi. 1997. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother. 41:1399-1402.
22. Rodvold, K. A. 1999. Clinical pharmacokinetics of clarithromycin. Clin. Pharmacokinet. 37:385-398.
23. Taninaka, C., H. Ohtani, E. Hanada, H. Kotaki, H. Sato, and T. Iga. 2000. Determination of erythromycin, clarithromycin, roxithromycin and azithromycin in plasma by high-performance liquid chromatography with amperometric detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 738:405-411.
24. Tessier, P. R., M. K. Kim, W. Zhou, D. Xuan, C. Li, M. Ye, C. H. Nightingale, and D. P. Nicolau. 2002. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob. Agents Chemother. 46:1425-1434.
25. Zhou, S., S. Yung Chan, B. Cher Goh, E. Chan, W. Duan, M. Huang, and H. L. McLeod. 2005. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44:297-304.